343 related articles for article (PubMed ID: 27449873)
1. Acceptability and feasibility of 400 μg buccal misoprostol after 200 mg mifepristone for early medical abortion in Georgia.
Tsereteli T; Chong E; Louie K; Bokhua Z; Winikoff B
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):367-71. PubMed ID: 27449873
[TBL] [Abstract][Full Text] [Related]
2. Acceptability and feasibility of the use of 400 μg of sublingual misoprostol after mifepristone for medical abortion up to 63 days since the last menstrual period: evidence from Uzbekistan.
Raghavan S; Tsereteli T; Kamilov A; Kurbanbekova D; Yusupov D; Kasimova F; Jymagylova D; Winikoff B
Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):104-11. PubMed ID: 23387475
[TBL] [Abstract][Full Text] [Related]
3. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
[TBL] [Abstract][Full Text] [Related]
4. Acceptability and feasibility of outpatient medical abortion with mifepristone and misoprostol up to 70 days gestation in Singapore.
Tan YL; Singh K; Tan KH; Gosavi A; Koh D; Abbas D; Winikoff B
Eur J Obstet Gynecol Reprod Biol; 2018 Oct; 229():144-147. PubMed ID: 30179732
[TBL] [Abstract][Full Text] [Related]
5. Acceptability and feasibility of medical abortion with mifepristone and misoprostol in Nigeria.
Okonofua F; Shittu O; Shochet T; Diop A; Winikoff B
Int J Gynaecol Obstet; 2014 Apr; 125(1):49-52. PubMed ID: 24507887
[TBL] [Abstract][Full Text] [Related]
6. Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days.
Kopp Kallner H; Fiala C; Stephansson O; Gemzell-Danielsson K
Hum Reprod; 2010 May; 25(5):1153-7. PubMed ID: 20172871
[TBL] [Abstract][Full Text] [Related]
7. Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation.
Løkeland M; Iversen OE; Engeland A; Økland I; Bjørge L
Acta Obstet Gynecol Scand; 2014 Jul; 93(7):647-53. PubMed ID: 24766569
[TBL] [Abstract][Full Text] [Related]
8. Early medical abortion using low-dose mifepristone followed by buccal misoprostol: a large Australian observational study.
Goldstone P; Michelson J; Williamson E
Med J Aust; 2012 Sep; 197(5):282-6. PubMed ID: 22938126
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and acceptability of a mifepristone-misoprostol combined regimen for early induced abortion among women in Mexico City.
Peña M; Dzuba IG; Smith PS; Mendoza LJ; Bousiéguez M; Martínez ML; Polanco RR; Villalón AE; Winikoff B
Int J Gynaecol Obstet; 2014 Oct; 127(1):82-5. PubMed ID: 24957534
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled trial of different buccal misoprostol doses in mifepristone medical abortion.
Chong E; Tsereteli T; Nguyen NN; Winikoff B
Contraception; 2012 Sep; 86(3):251-6. PubMed ID: 22305917
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
Gatter M; Cleland K; Nucatola DL
Contraception; 2015 Apr; 91(4):269-73. PubMed ID: 25592080
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
Faucher P; Baunot N; Madelenat P
Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
[TBL] [Abstract][Full Text] [Related]
13. Introducing medication abortion into public sector facilities in KwaZulu-Natal, South Africa: an operations research study.
Blanchard K; Lince-Deroche N; Fetters T; Devjee J; de Menezes ID; Trueman K; Sudhinaraset M; Nkonko E; Moodley J
Contraception; 2015 Oct; 92(4):330-8. PubMed ID: 26162575
[TBL] [Abstract][Full Text] [Related]
14. Preference and acceptability of oral versus vaginal administration of misoprostol in medical abortion with mifepristone.
Arvidsson C; Hellborg M; Gemzell-Danielsson K
Eur J Obstet Gynecol Reprod Biol; 2005 Nov; 123(1):87-91. PubMed ID: 16260342
[TBL] [Abstract][Full Text] [Related]
15. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao.
Boersma AA; Meyboom-de Jong B; Kleiverda G
Eur J Contracept Reprod Health Care; 2011 Apr; 16(2):61-6. PubMed ID: 21303309
[TBL] [Abstract][Full Text] [Related]
16. Feasibility, efficacy, safety, and acceptability of mifepristone-misoprostol for medical abortion in the Democratic People's Republic of Korea.
Tran NT; Jang MC; Choe YS; Ko WS; Pyo HS; Kim OS
Int J Gynaecol Obstet; 2010 Jun; 109(3):209-12. PubMed ID: 20206354
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period.
Middleton T; Schaff E; Fielding SL; Scahill M; Shannon C; Westheimer E; Wilkinson T; Winikoff B
Contraception; 2005 Nov; 72(5):328-32. PubMed ID: 16246656
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and acceptability of early mifepristone-misoprostol medical abortion in Ukraine: results of two clinical trials.
Raghavan S; Maistruk G; Shochet T; Bannikov V; Posohova S; Zhuk S; Lishchuk V; Winikoff B
Eur J Contracept Reprod Health Care; 2013 Apr; 18(2):112-9. PubMed ID: 23465062
[TBL] [Abstract][Full Text] [Related]
19. Acceptability and feasibility of medical abortion in Nepal.
Karki C; Pokharel H; Kushwaha A; Manandhar D; Bracken H; Winikoff B
Int J Gynaecol Obstet; 2009 Jul; 106(1):39-42. PubMed ID: 19345944
[TBL] [Abstract][Full Text] [Related]
20. Randomized trial of oral versus sublingual misoprostol 24 h after mifepristone for medical abortion.
Dahiya K; Mann S; Nanda S
Arch Gynecol Obstet; 2011 Jul; 284(1):59-63. PubMed ID: 20652288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
